PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Full description

Saved in:
Bibliographic Details
Main Authors: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Format: Artigo
Language:Inglês
Published: Paediatrician Publishers, LLC 2012-08-01
Series:Pediatričeskaâ Farmakologiâ
Subjects:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Online Access:https://www.pedpharma.ru/jour/article/view/302
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items